Bill > HRes803

This resolution urges the Director of the Food and Drug Administration (FDA) to conduct a comprehensive safety review of chemical abortion drugs, specifically mifepristone, in response to concerns about expanded access and potential risks. The resolution highlights that the Obama and Biden administrations have progressively reduced restrictions on chemical abortion drugs, including eliminating in-person administration requirements and allowing mail distribution. The document notes that chemical abortions now represent more than half of all abortions in the United States, and independent research suggests that serious complications may be significantly underreported compared to official FDA and manufacturer data. The resolution calls on the FDA to reevaluate the safety of these drugs by examining recent independent studies and to publicly release a comprehensive safety review that includes real-world outcomes and potential complications. The resolution also raises broader concerns about potential ethical issues, including the use of taxpayer funding for providers and potential risks of coercion, domestic abuse, and intentional misuse of abortion medications.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-resolution/803/all-info